Abstract
Triple negative breast cancer (TNBC) is a heterogeneous disease entity constituting about 15% of breast cancer cases worldwide. TNBC is associated with poor prognosis and lack of sustained response to conventional chemotherapeutic agents. Tumoral heterogeneity and the presence of several subtypes of TNBC such as Basal like (BL)-1, BL-2, immune-modulatory, luminal androgen receptor, mesenchymal, and mesenchymal/stem like subtype and claudin low subtype, may explain some of the difficulties faced in managing this challenging disease subgroups.
Although no approved targeted therapy is available for TNBCs, molecular-profiling efforts have revealed promising molecular targets such as the vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), polyadenosine ribose polymerase inhibitors (PARPi) and DNA repair pathway, androgen pathway, and NOTCH pathway. TNBC is subject to intense research activities aiming at dissecting potential pathways, identifying potential molecular signatures and biomarkers in order to properly develop new targeted biologic modifiers. Despite this, there is a lack of approved predictive and prognostic biomarkers, and keeping in view the complexity of TNBC biology, research should be targeted towards identifying multi-factorial signatures rather than single markers. This review aims to summarize the current evidence, ongoing research and discuss future strategies for the treatment of patients with TNBC. In addition we have reviewed the recent advances in detecting predictive and prognostic biomarkers and identifying surrogate markers for early identification of potential responders to the new therapies.Keywords: Triple negative breast cancer, molecular pathways, VEGF, EGFR, target therapy.
Anti-Cancer Agents in Medicinal Chemistry
Title:Triple Negative Breast Cancer: A Tale of Two Decades
Volume: 17 Issue: 4
Author(s): Arwa M. Ali*, Jawaher A.K. Ansari, Nashwa M. Abd El-Aziz, Waleed N. Abozeed, Ahmed M. Abdel Warith, Khalid Alsaleh and Jean-Marc Nabholtz
Affiliation:
- Oncology Center, King Khalid University Hospital, King Saud University,Saudi Arabia
Keywords: Triple negative breast cancer, molecular pathways, VEGF, EGFR, target therapy.
Abstract: Triple negative breast cancer (TNBC) is a heterogeneous disease entity constituting about 15% of breast cancer cases worldwide. TNBC is associated with poor prognosis and lack of sustained response to conventional chemotherapeutic agents. Tumoral heterogeneity and the presence of several subtypes of TNBC such as Basal like (BL)-1, BL-2, immune-modulatory, luminal androgen receptor, mesenchymal, and mesenchymal/stem like subtype and claudin low subtype, may explain some of the difficulties faced in managing this challenging disease subgroups.
Although no approved targeted therapy is available for TNBCs, molecular-profiling efforts have revealed promising molecular targets such as the vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), polyadenosine ribose polymerase inhibitors (PARPi) and DNA repair pathway, androgen pathway, and NOTCH pathway. TNBC is subject to intense research activities aiming at dissecting potential pathways, identifying potential molecular signatures and biomarkers in order to properly develop new targeted biologic modifiers. Despite this, there is a lack of approved predictive and prognostic biomarkers, and keeping in view the complexity of TNBC biology, research should be targeted towards identifying multi-factorial signatures rather than single markers. This review aims to summarize the current evidence, ongoing research and discuss future strategies for the treatment of patients with TNBC. In addition we have reviewed the recent advances in detecting predictive and prognostic biomarkers and identifying surrogate markers for early identification of potential responders to the new therapies.Export Options
About this article
Cite this article as:
Ali M. Arwa*, Ansari A.K. Jawaher, El-Aziz M. Abd Nashwa, Abozeed N. Waleed, Warith M. Abdel Ahmed, Alsaleh Khalid and Nabholtz Jean-Marc, Triple Negative Breast Cancer: A Tale of Two Decades, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (4) . https://dx.doi.org/10.2174/1871520616666160725112335
DOI https://dx.doi.org/10.2174/1871520616666160725112335 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets Supramolecular Chiro-Biomedical Assays and Enantioselective HPLC Analyses for Evaluation of Profens as Non-Steroidal Anti-Inflammatory Drugs, Potential Anticancer Agents and Common Xenobiotics
Current Drug Discovery Technologies Editorial (Thematic Issue: Bioinformatics and Biotechnology)
Current Biotechnology Recent Advances in Radiation Therapy of Cancer Cells: A Step towards an Experimental and Systems Biology Framework
Current Radiopharmaceuticals Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology In Silico Prediction Models for Blood-Brain Barrier Permeation
Current Medicinal Chemistry Progress in Chemo- and Regioselective Transformations of Symmetrical Cephalostatin Analogues
Letters in Organic Chemistry Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes
Current Drug Targets Critical Review of the Evidence on 5-Aminosalicilate for Chemoprevention of Colorectal Cancer in Ulcerative Colitis: A Methodological Question
Current Clinical Pharmacology The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Solanum nigrum Anticancer Effect Through Epigenetic Modulations in Breast Cancer Cell Lines
Current Cancer Therapy Reviews The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment
Current Pharmaceutical Design Lymphatic Drainage in Patients with Primary Cutaneous Melanoma - the Role of Lymphoscintigraphy in Sentinel Lymph Node Biopsy
Current Medical Imaging MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
Current Drug Metabolism Systems Biology: A Powerful Tool for Drug Development
Current Topics in Medicinal Chemistry Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry